Baxter International Inc. recently announced the FDA has indicated that the company may begin a prospective, multicenter clinical trial to test its new on-demand PD generation system that is meant to ease the patient’s experience through use at home, according to a press release from the company.
The clinical trial will assess the effectiveness and safety of the technology, which employs a small water filtration device, turning tap water into dialysis solution to complete therapy sessions, according to the release. This will create a flexible means for individualized patient care.
“We are on a journey to transform how kidney disease is identified, managed and treated, with a focus on improving outcomes for patients,” Laura Angelini, general manager of Baxter’s renal care business, said in the release. “Our on-demand technology is the cornerstone of our innovation pipeline, as we believe the technology will open up new possibilities for therapy delivery while improving the experience for patients today.”